Q3 Earnings Estimate for Labcorp Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its Q3 2025 earnings estimate for Labcorp to $4.11 per share, slightly up from its previous forecast of $4.10.
• Labcorp reported a 9.6% increase in quarterly revenue year-over-year, totaling $3.53 billion, and beat analysts' expectations for EPS in its last earnings report.
• The company declared a quarterly dividend of $0.72, with a dividend yield of 1.0%, to be paid on December 11th to shareholders on record by November 26th.

Labcorp Holdings Inc. (NYSE:LH - Free Report) - Research analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for Labcorp in a report issued on Wednesday, October 8th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $4.11 per share for the quarter, up from their prior forecast of $4.10. The consensus estimate for Labcorp's current full-year earnings is $16.01 per share. Leerink Partnrs also issued estimates for Labcorp's FY2027 earnings at $20.02 EPS and FY2028 earnings at $22.61 EPS.

Labcorp (NYSE:LH - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $4.35 EPS for the quarter, beating analysts' consensus estimates of $4.14 by $0.21. Labcorp had a return on equity of 15.45% and a net margin of 5.66%.The company had revenue of $3.53 billion during the quarter, compared to the consensus estimate of $3.49 billion. During the same period in the previous year, the firm posted $3.94 earnings per share. Labcorp's quarterly revenue was up 9.6% compared to the same quarter last year. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS.

Several other equities analysts also recently issued reports on LH. Robert W. Baird set a $311.00 price objective on Labcorp in a research report on Monday, August 25th. Hsbc Global Res downgraded Labcorp from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Evercore ISI upped their price target on Labcorp from $300.00 to $305.00 and gave the company an "outperform" rating in a report on Friday, October 3rd. Barclays upped their price target on Labcorp from $275.00 to $290.00 and gave the company an "equal weight" rating in a report on Thursday, October 2nd. Finally, Wall Street Zen raised Labcorp from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Ten investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $292.00.

Labcorp Stock Performance

Shares of LH stock opened at $277.46 on Thursday. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average of $274.61 and a two-hundred day moving average of $255.28. Labcorp has a 52 week low of $209.38 and a 52 week high of $289.20. The company has a market cap of $23.06 billion, a P/E ratio of 30.62, a PEG ratio of 1.79 and a beta of 0.89.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Wednesday, November 26th will be paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.0%. Labcorp's payout ratio is presently 31.79%.

Insider Activity at Labcorp

In other news, CEO Adam H. Schechter sold 5,643 shares of Labcorp stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $266.78, for a total value of $1,505,439.54. Following the completion of the transaction, the chief executive officer owned 93,319 shares in the company, valued at approximately $24,895,642.82. The trade was a 5.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kerrii B. Anderson sold 3,500 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $280.00, for a total transaction of $980,000.00. Following the completion of the sale, the director directly owned 8,666 shares of the company's stock, valued at approximately $2,426,480. This represents a 28.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 15,046 shares of company stock worth $4,074,692 in the last three months. Corporate insiders own 0.84% of the company's stock.

Hedge Funds Weigh In On Labcorp

Several institutional investors and hedge funds have recently made changes to their positions in LH. Norges Bank acquired a new position in Labcorp in the 2nd quarter worth $263,070,000. Lazard Asset Management LLC lifted its position in Labcorp by 224.1% during the 2nd quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company's stock worth $259,734,000 after buying an additional 684,153 shares in the last quarter. Select Equity Group L.P. lifted its position in Labcorp by 39.1% during the 1st quarter. Select Equity Group L.P. now owns 2,220,056 shares of the medical research company's stock worth $516,696,000 after buying an additional 624,099 shares in the last quarter. Nordea Investment Management AB lifted its position in Labcorp by 28.2% during the 2nd quarter. Nordea Investment Management AB now owns 1,829,039 shares of the medical research company's stock worth $476,995,000 after buying an additional 401,808 shares in the last quarter. Finally, Invesco Ltd. lifted its position in Labcorp by 28.9% during the 1st quarter. Invesco Ltd. now owns 1,421,112 shares of the medical research company's stock worth $330,750,000 after buying an additional 318,865 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company's stock.

About Labcorp

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.